Sun Pharma to consider ₹15,000 crore NCD issue; board meeting on 12 October
Sun Pharmaceutical pursued an acquisition in a governance development with 12 October in focus.
7 Oct 2026 · LiveMint Markets
Sun Pharmaceutical Industries will hold a Board meeting on October 12, 2026, to approve the issuance of non-convertible debentures worth up to ₹15,000 crore to fund a bridge loan for acquiring Organon & Co.
Key facts
- Dates in focus
- 12 October and October 12
The analysis
Sun Pharmaceutical reported ₹15,000 crore. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is -1.3% on the day at ₹1,781.00, and has returned -6.4% over three months. It sits 11% below its 52-week high. The pharma & healthcare sector has moved +1.3% over the same period, so Sun Pharmaceutical is running 7.7 points behind its peers.
For Sun Pharmaceutical, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Governance events hit the valuation multiple, not just the earnings — and the de-rating is usually faster than the recovery.
Market context
- The company directly in focus is SUNPHARMA.
- Sector exposure: Pharma & Healthcare.
In this story
Related coverage
Valiant Organics among 5 commodity stocks that hit 52-week highs and rallied up to 48% in a month
Congress Calls For Nationwide Protests On October 8; Declares Oct 7 'Black Day' Amid CEC Row Detentions
Taking Stock: Market fails to hold on to day#39;s gains, ends marginally higher
Penny stock under ₹10 hits 5% upper circuit after this fundraising update | Do you own?
Rahul Gandhi, Congress MPs Released From Detention After High-Stakes Protest Outside EC Office | Watch